Figure 2.
OS in patients treated with Ven-Aza in favorable-, intermediate-, and adverse-risk groups. OS in patients treated with Ven-Aza by risk group per (A) ELN 2017 and (B) ELN 2022.

OS in patients treated with Ven-Aza in favorable-, intermediate-, and adverse-risk groups. OS in patients treated with Ven-Aza by risk group per (A) ELN 2017 and (B) ELN 2022.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal